Kovo HealthTech Corporation to Change Name
Kovo HealthTech Corporation to Change Name
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2024) - Kovo HealthTech Corporation (TSXV: KOVO) ("Kovo" or the "Company") is pleased to announce that it will be changing its name from "Kovo HealthTech Corporation" to "Kovo+ Holdings Inc." (the "Name Change"), effective pre-market open on October 28, 2024.
不列颠哥伦比亚省温哥华--(Newsfile Corp.,2024年10月23日)——科沃健康科技公司(多伦多证券交易所股票代码:KOVO)(“Kovo” 或 “公司”)欣然宣布,它将把名称从 “Kovo HealthTech Corporation” 改为 “Kovo+ Holdings Inc.”(“更名”),于2024年10月28日开盘前生效。
"Along with our upcoming rebrand, the Name Change more accurately reflects our evolving focus and marks the Company's pivot to broader opportunities while continuing to build upon its continued focus on the healthcare sector," said Brenner Adams, Interim CEO of the Company.
该公司临时首席执行官布伦纳·亚当斯表示:“除了我们即将进行的品牌重塑外,更名更正地反映了我们不断变化的重点,标志着公司转向更广泛的机会,同时继续在对医疗保健行业的持续关注的基础上再接再厉。”
In connection with the Name Change, no action will be required by existing shareholders, nor will any certificates representing common shares of the Company ("Common Shares") be affected or need to be exchanged. A new CUSIP number has been obtained to replace the previous CUSIP number, and Kovo's Common Shares will continue trading under the symbol "KOVO". The Company encourages any shareholder with any questions or concerns to discuss any of the foregoing with their broker or agent.
就名称变更而言,现有股东无需采取任何行动,任何代表公司普通股(“普通股”)的证书也不会受到影响或需要交换。已经获得了新的CUSIP号码以取代之前的CUSIP号码,Kovo的普通股将继续以 “KOVO” 的代码进行交易。公司鼓励任何有任何问题或疑虑的股东与其经纪人或代理人讨论上述任何问题。
The Name Change was approved by the Company's board of directors and the TSX Venture Exchange ("TSXV"). Concurrent with the Name Change, the Company intends to file its certificate of name change effective pre-market open on October 28, 2024.
更名已获得公司董事会和多伦多证券交易所风险投资交易所(“TSXV”)的批准。在名称变更的同时,公司打算自2024年10月28日开盘前起提交名称变更证书。
About Kovo+ Holdings Inc.
关于 Kovo+ Holdings Inc.
Kovo+ is a versatile technology company leading the charge in AI initiatives to drive impact and innovation across diverse industries. Kovo+'s expanded vision and mission evaluates initiatives across diverse industry markets. Kovo+ remains committed to integrate strategic growth opportunities with mid-market Medical Billing firms for exploitive business optimization synergies and expanding the Kovo+ RCM (revenue cycle management) business model. Kovo+ also integrates accretive additions in the broader healthcare sector to its portfolio. Dedicated to revolutionizing business processes optimization through technological advancements and evolving AI applied methods, Kovo+ embodies a commitment to ensured and enduring profitability. To learn more about Kovo+ and to keep up to date on Kovo+ news, visit m.
Kovo+ 是一家多才多艺的科技公司,在人工智能计划方面处于领先地位,旨在推动不同行业的影响力和创新。Kovo+ 扩大的愿景和使命评估了不同行业市场的举措。Kovo+ 仍然致力于与中端市场医疗账单公司整合战略增长机会,以发挥业务优化协同效应,扩大Kovo+ RcM(收入周期管理)业务模式。Kovo+ 还将更广泛的医疗保健领域的增值新增产品纳入其产品组合。Kovo+ 致力于通过技术进步和不断演变的人工智能应用方法来彻底改变业务流程优化,体现了对确保和持久盈利能力的承诺。要了解有关 Kovo+ 的更多信息并及时了解 Kovo+ 的最新消息,请访问 m.
Cautionary Note Regarding Forward-Looking Statements
关于前瞻性陈述的警示说明
This press release contains forward-looking information. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as "anticipate", "proposed", "estimates", "would", "expects", "intends", "plans", "may", "will", and similar expressions. More particularly and without limitation, the forward‐looking statements in this press release include (i) expectations regarding the value drivers and anticipated benefits of the Name Change; (ii) expectations regarding the timing that Kovo's Common Shares will commence trading on the TSXV following the Name Change; and (iii) expectations concerning the Company's business plans and operations. Forward-looking statements or information are based on a number of factors and assumptions that have been used to develop such statements and information, but which may prove to be incorrect. Although Kovo believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this press release reflects the current expectations, assumptions and/or beliefs of Kovo based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement.
本新闻稿包含前瞻性信息。提供此类前瞻性陈述或信息的目的是向公司股东和潜在投资者通报管理层当前对未来的预期和计划。请读者注意,依赖此类信息可能不适合用于其他目的。任何此类前瞻性信息都可以用 “预期”、“提议”、“估计”、“将”、“期望”、“打算”、“计划”、“可能”、“将” 等词语和类似的表述来识别。更具体地说,但不限于,本新闻稿中的前瞻性声明包括(i)对名称变更的价值驱动因素和预期收益的预期;(ii)对Kovo普通股在更名后在多伦多证券交易所开始交易的时间的预期;(iii)对公司业务计划和运营的预期。前瞻性陈述或信息基于许多因素和假设,这些因素和假设已被用来制定此类陈述和信息,但事实证明这些因素和假设可能不正确。尽管Kovo认为此类前瞻性陈述或信息中反映的预期是合理的,但不应过分依赖前瞻性陈述,因为公司无法保证此类预期会被证明是正确的。根据公司目前获得的信息,本新闻稿中的前瞻性信息反映了Kovo当前的预期、假设和/或信念。任何前瞻性信息仅代表截至发布之日,除非适用的证券法另有要求,否则公司不承担任何更新任何前瞻性信息的意图或义务,无论这些信息是由于新信息、未来事件或业绩导致的,还是本警示声明的明确限定的。
Contact Information
联系信息
For further information, please contact:
欲了解更多信息,请联系:
Peter Bak, Board Chair
investors@kovo.co
1-866-558-6777
彼得·巴克,董事会主席
investors@kovo.co
1-866-558-6777
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.
多伦多证券交易所风险交易所及其监管服务提供商(该术语在多伦多证券交易所风险交易所的政策中定义)均不对本新闻稿的充分性承担责任。
译文内容由第三方软件翻译。